Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602
Source: Reumatismo - Category: Rheumatology Authors: Source Type: research